enGene Therapeutics Inc.
NCM: ENGNLive Quote
About enGene Therapeutics Inc.
Healthcare
Biotechnology
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
📊 Fundamental Analysis
enGene Therapeutics Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -46.1%, which indicates that capital utilization is currently under pressure.
At a current price of $7.20, ENGN currently sits at the 47th percentile of its 52-week range (Range: $2.65 - $12.25).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$111.87M
Trailing P/E
--
Forward P/E
-3.79
Beta (5Y)
-0.05
52W High
$12.25
52W Low
$2.65
Avg Volume
429K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App